yes, spot on, Scott. IMO, the biggest mistake was to roll the dice and plant the spear on '3D' instead of advancing with a unsurmountable time lead advantage with Preeclampsia.
IMHO, Zami made a bet on '3D' and used the funds that WERE available for expedited, fast-track, orphan designated indications like Preeclampsia and Buergers Disease, which several of the predictable's here, have mocked...
TODAY we have NO time lead and NO revenue.
NOBODY knows ENVIVO whether 3D cells would be ANY better than 2D cells...…. and we may never know...
News 
Market Data 
Discover 
